Eupraxia Pharmaceuticals Inc (EPRX) Smart Money Holdings (13F, Q2 2026)

EPRX ranks #5443 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

68 institutions disclose a position in EPRX, but none treat it as a major bet — even Great Point Partners LLC, its most concentrated holder, allocates just 1.5% of its own portfolio to it.

Jane Street Group, LLC has added to its EPRX position for two straight quarters, increasing it by $1.9M to reach $2.2M today.

Beutel, Goodman & Co Ltd. has trimmed its EPRX position for two straight quarters, cutting it by $4.1M while still holding $23.8M.

EPRX is up 17.5% today, and institutions have been net buyers of $17.9M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

EPRX reported a net loss of $38.6M in its latest fiscal year.

• Not yet profitable — net loss of $38.6M in the latest fiscal year
• Net income declined year over year, from -$25.5M to -$38.6M
• Operating cash flow was negative, using $28.6M in cash
• Current ratio of 15.12x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.07x equity — within a conventional range